$VMD

Viemed Healthcare reported Q2 2026 revenue of $78.1M (up 24% Y-o-Y) and Adjusted EBITDA of $13.7M. The company announced a new share repurchase program for up to 5% of outstanding shares, following a strong first half with 680,802 shares repurchased. Full-year 2026 guidance is $314M-$320M in revenue and $64M-$68M in Adjusted EBITDA. The company has a strong balance sheet with $10.7M in cash and no net debt as of June 30, 2026.

VieMed Healthcare reported 2025 results with $270.3M revenue, $61.4M Adjusted EBITDA, and $28.1M free cash flow. For 2026, it projects $314M–$320M revenue and $64M–$68M Adjusted EBITDA, with a new share buyback program. The company highlights growth, cash generation, and strategic initiatives.

Viemed Healthcare (VMD) director Randy E. Dobbs settled 16,763 Restricted Stock Units and 4,191 Phantom Share Units, acquiring and then disposing of 4,191 common shares at $8.94 each. He also received a new grant of 16,848 RSUs, vesting in 2027. The transactions reflect insider equity award activity.

Viemed Healthcare (VMD) director Sabrina Heltz exercised 15,029 RSUs and 3,757 Phantom Share Units, converting them into common shares. She also received new grants of 12,174 RSUs and 3,043 Phantom Share Units, set to vest in 2027. The Phantom Share Units were settled at $8.94 per share.

Viemed Healthcare (VMD) director Timothy Smokoff exercised 15,029 RSUs and settled 3,757 Phantom Share Units, returning 3,757 common shares to the company at $8.94 per share. He also received new grants of 12,174 RSUs and 3,043 Phantom Share Units, both vesting in one year. Transactions were not under a Rule 10b5-1 plan.

Viemed Healthcare (VMD) reported Q2 2026 revenue of $78.1M, up 24% year over year, with ventilator patient counts reaching 12,635. Adjusted EBITDA was $13.7M (17.6% margin) and net income was $2.8M. Full-year 2026 revenue guidance was raised to $314M-$320M and adjusted EBITDA to $64M-$68M.

Viemed Healthcare (NASDAQ:VMD) reported Q2 updates on home respiratory and sleep therapies. Management cited improved ventilator patient growth and said PAP setups rose, with sleep patients up about 5% sequentially and 44% YoY. Equipment sales nearly doubled to $19M. Gross profit was $45M (57.7% margin). Full-year net revenue guidance raised to $314M-$320M and adjusted EBITDA to $64M-$68M.

Viemed Healthcare (NASDAQ:VMD) reported Q2 2026 results for the three and six months ended June 30, 2026 and updated 2026 guidance. Cash was $10.7M, working capital $6.1M, and it repaid $2.2M of a term loan. Net revenue guidance was raised at the low end; net capex is now 8.5% to 10.0% of net revenue.

VIEMED HEALTHCARE, INC. (VMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. VIEMED HEALTHCARE ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS Lafayette, Louisiana (August 3, 2026) Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national provider of technology-enabled, home-based healthcare solutions and chronic disease management, ann

Viemed Healthcare, Inc. (VMD) is scheduled to report Q2 2026 earnings on Aug. 3 at 8:00 AM ET. The consensus outlook cited for Q2 2026 calls for revenue of $78.0 million and EPS of $0.12, with figures stated in USD.